Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pitavastatin - Kowa

Next Previous
Drug Profile

Pitavastatin - Kowa

Alternative Names: Alipza; Itavastatin; Livalo; Livazo; Nisvastatin; NK 104; NK-104-CR; NK-104-LH; NK-104-PH; NKS 104; P 872441; Pitavastatin Calcium; Redevant; Trolise; Vezepra

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nissan Chemical Industries
  • Developer AbbVie; Algorithm; Daiichi Sankyo Company; Eli Lilly; ESTEVE; JW Pharmaceutical; Kowa; Mitsubishi Tanabe Pharma Corporation; Nissan Chemical Industries; Recordati
  • Class Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
  • Registered Hyperlipoproteinaemia type IIa
  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Jan 2019 The US District Court, Southern District of New York, upholds patent (patent numbers 8 557 993) protection for pitavastatin
  • 02 Aug 2018 Merck completes a phase I pharmacokinetic trial in patients with renal insufficiency in USA (PO) (NCT03311841)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top